INT93137

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2001
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 17
Total Number 17
Disease Relevance 4.51
Pain Relevance 6.49

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Map2k1) Golgi apparatus (Map2k1) cytoplasm (Map2k1)
cell proliferation (Map2k1) cytosol (Map2k1) mitosis (Map2k1)
Anatomy Link Frequency
spinal 1
blood vessels 1
corpus striatum 1
hearts 1
Map2k1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
antagonist 9 99.96 Very High Very High Very High
Morphine 13 99.56 Very High Very High Very High
intrathecal 7 99.50 Very High Very High Very High
Rostral ventrolateral medulla 55 99.38 Very High Very High Very High
opioid receptor 12 99.04 Very High Very High Very High
narcan 2 98.64 Very High Very High Very High
Kinase C inhibitor 3 98.08 Very High Very High Very High
dorsal root ganglion 9 96.56 Very High Very High Very High
cerebral cortex 4 96.00 Very High Very High Very High
bradykinin 24 95.72 Very High Very High Very High
Disease Link Frequency Relevance Heat
Middle Cerebral Artery Infarction 55 98.16 Very High Very High Very High
Stress 23 97.74 Very High Very High Very High
Ganglion Cysts 12 96.56 Very High Very High Very High
Apoptosis 10 96.00 Very High Very High Very High
Cv Unclassified Under Development 16 91.04 High High
Pressure Volume 2 Under Development 7 90.52 High High
Pressure And Volume Under Development 23 87.04 High High
Death 78 84.72 Quite High
Coronary Heart Disease 5 83.88 Quite High
Coronary Artery Disease 2 82.76 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Evaluation of stress signaling pathways following in vivo challenge of lethal toxin (2 µg/g, b.w., i.p.) for 18 hrs revealed overtly downregulated MEK1/2, phospho-MAP kinase and phospho-ERK associated with hyperactivation of JNK in murine hearts (Fig. 10).
Negative_regulation (downregulated) of MEK1 in hearts associated with stress
1) Confidence 0.42 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2954163 Disease Relevance 0.66 Pain Relevance 0
Inhibition of ERK with the selective MEK-1 antagonist, PD 098059 during IPC or TAN-67 administration significantly reduced cardioprotection (41.5 +/- 6.4 and 63.0 +/- 4.8).
Negative_regulation (Inhibition) of MEK-1 associated with antagonist
2) Confidence 0.41 Published 2001 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 11160653 Disease Relevance 0.16 Pain Relevance 0.40
In our first experiment, we tested whether changes in CREB expression and CREB phosphorylation could be regulated by MAP kinase activity, The intrathecal application of U0126, a MEK 1/2 inhibitor (dissolved in 10% DMSO, 1 ?
Negative_regulation (inhibitor) of MEK 1 associated with intrathecal
3) Confidence 0.41 Published 2005 Journal Mol Pain Section Body Doc Link PMC1224868 Disease Relevance 0 Pain Relevance 0.47
Application of PD 98059, a selective MEK1/2 inhibitor, strongly antagonized the effect of magnolol.
Negative_regulation (inhibitor) of MEK1
4) Confidence 0.41 Published 2008 Journal Exp. Biol. Med. (Maywood) Section Abstract Doc Link 18641058 Disease Relevance 0.62 Pain Relevance 0.09
PD98059, a MEK1/2 inhibitor, abolished both ERK1/2 activation and infarct size limitation by DADLE.
Negative_regulation (inhibitor) of MEK1
5) Confidence 0.41 Published 2006 Journal Basic Res. Cardiol. Section Abstract Doc Link 16619106 Disease Relevance 0.33 Pain Relevance 0.44
Pretreatment of rats with SL 327 (a selective MEK1/2 inhibitor that blocks ERK activation) fully prevented the reduction of FADD content induced by SNC-80 in the cerebral cortex (43%) and corpus striatum (29%), demonstrating the direct involvement of ERK1/2 signaling in the regulation of FADD by the opiate agonist.
Negative_regulation (inhibitor) of MEK1 in corpus striatum associated with agonist, opiate and cerebral cortex
6) Confidence 0.41 Published 2007 Journal Neuropsychopharmacology Section Abstract Doc Link 16482086 Disease Relevance 0.19 Pain Relevance 1.19
Furthermore, bradykinin-induced prostaglandin E(2) release was inhibited following treatment with the phospholipase A(2) inhibitor, arachidonyltrifluoromethyl ketone (AACOCF(3)), the nonselective cyclooxygenase inhibitor, piroxicam, the mitogen-activated protein kinase kinase-1 (MEK1) inhibitor, 2'-amino-3'-methoxyflavone (PD98059), and the protein kinase C inhibitor, bisindolylmaleimide XI (Ro320432).
Negative_regulation (inhibitor) of MEK1 associated with bradykinin and kinase c inhibitor
7) Confidence 0.38 Published 2003 Journal Eur. J. Pharmacol. Section Abstract Doc Link 12782182 Disease Relevance 0.20 Pain Relevance 0.76
Furthermore, bradykinin-induced prostaglandin E(2) release was inhibited following treatment with the phospholipase A(2) inhibitor, arachidonyltrifluoromethyl ketone (AACOCF(3)), the nonselective cyclooxygenase inhibitor, piroxicam, the mitogen-activated protein kinase kinase-1 (MEK1) inhibitor, 2'-amino-3'-methoxyflavone (PD98059), and the protein kinase C inhibitor, bisindolylmaleimide XI (Ro320432).
Negative_regulation (inhibitor) of mitogen-activated protein kinase kinase-1 associated with bradykinin and kinase c inhibitor
8) Confidence 0.38 Published 2003 Journal Eur. J. Pharmacol. Section Abstract Doc Link 12782182 Disease Relevance 0.20 Pain Relevance 0.77
Naloxone effectively blocked these actions of morphine, whereas a selective MEK1 inhibitor, PD98059, inhibited the morphine-induced increase in the phosphorylation of ERK and CREB, and the expression of CGRP and SP.
Negative_regulation (inhibitor) of MEK1 associated with narcan, substance p and morphine
9) Confidence 0.26 Published 2001 Journal Eur. J. Neurosci. Section Abstract Doc Link 11683901 Disease Relevance 0.66 Pain Relevance 1.58
Hence, combined with our findings, we extrapolate from the previous results that it is probably due to the differential distribution of ERK kinase, MEK1 or MEK2 or other unknown additional members of this kinase family, that leads to the differential distribution of pERK1 and pERK2 between spinal and supraspinal level under normal state observed in the present study.
Negative_regulation (distribution) of MEK1 in spinal
10) Confidence 0.20 Published 2007 Journal BMC Neurosci Section Body Doc Link PMC1949833 Disease Relevance 0.07 Pain Relevance 0.37
Similar results were obtained on local application bilaterally into RVLM of U0126 (5 pmol), a specific inhibitor of MEK1 and MEK2 [26,27] (fig. 1).
Negative_regulation (inhibitor) of MEK1 associated with rostral ventrolateral medulla
11) Confidence 0.17 Published 2010 Journal J Biomed Sci Section Body Doc Link PMC2848001 Disease Relevance 0.52 Pain Relevance 0.25
The specificity of U0126 has been tested in numerous studies previously [13,18] on isolated cells and in vivo; we have performed this on cerebral blood vessels with and without the MEK1 inhibitor [20,27].
Negative_regulation (inhibitor) of MEK1 in blood vessels
12) Confidence 0.13 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2553085 Disease Relevance 0.41 Pain Relevance 0
Thus, it is reasonable to assume that the effect of U0126 is due to inhibition of cerebrovascular MEK1 activity.
Negative_regulation (inhibition) of MEK1
13) Confidence 0.13 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2553085 Disease Relevance 0.42 Pain Relevance 0.06
Blocking the ERK1/2 pathway with MEK1 inhibitor PD98059 (25 ?
Negative_regulation (inhibitor) of MEK1
14) Confidence 0.08 Published 2009 Journal Molecular & Cellular Proteomics : MCP Section Body Doc Link PMC2667352 Disease Relevance 0 Pain Relevance 0
Blocking the ERK1/2 pathway with MEK1 inhibitor PD98059 (25 ?
Negative_regulation (Blocking) of MEK1
15) Confidence 0.08 Published 2009 Journal Molecular & Cellular Proteomics : MCP Section Body Doc Link PMC2667352 Disease Relevance 0 Pain Relevance 0
Complementary experiments with specific kinase inhibitors showed that inhibition of MEK-1 by PD98059 reduced the stimulating effect of TGF-?
Negative_regulation (inhibition) of MEK-1
16) Confidence 0.08 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC2246241 Disease Relevance 0.07 Pain Relevance 0
In contrast, PD98059, a selective MEK-1 inhibitor, reduced the stimulatory effect of TGF-?
Negative_regulation (inhibitor) of MEK-1
17) Confidence 0.06 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC2246241 Disease Relevance 0 Pain Relevance 0.10

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox